The confirmed ORR as assessed by central review for both cutaneous and mucosal melanoma was 16.7% (3/18; 95% CI 3.6–41.4) for the patients with PD-L1-positive tumors and 36.4% (4/11; 95% CI 10.9–69.2) for the patients with PD-L1-negative tumors. The gene discussed is CD274; the disease is mucosal melanoma.